IMVT

Butchko Julia G.

Known title: Chief Dev. & Tech. OfficerCIK: 0001796290

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.

this person other insiders at IMVT

Transaction History

IMVT▼ Sell$93K
IMVT▼ Sell$4K
IMVT▼ Sell$80K
IMVT▼ Sell$5K
IMVT▼ Sell$43K
IMVT▼ Sell$96K
IMVT▼ Sell$225K
IMVT▼ Sell$69K
IMVT▼ Sell$33K
IMVT▲ Buy$0
IMVT▼ Sell$78K
IMVT▼ Sell$50K
IMVT▼ Sell$103K
IMVT▼ Sell$4K
IMVT▼ Sell$11K
IMVT▼ Sell$52K
IMVT▼ Sell$250K
IMVT▼ Sell$21
IMVT▼ Sell$29K
IMVT▼ Sell$24K
IMVT▲ Buy$0
IMVT▼ Sell$288
IMVT▼ Sell$1.0M
IMVT▼ Sell$9K
IMVT▼ Sell$2K
IMVT▼ Sell$3K
IMVT▲ Buy$0
IMVT▼ Sell$2K
IMVT▼ Sell$2K
IMVT▼ Sell$2K
IMVT▼ Sell$3K
IMVT▼ Sell$38K
IMVT▼ Sell$401K

We use analytics to understand how market-wall is used. No personal data is sold.